HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Differential effects of typical and atypical antipsychotics on brain myelination in schizophrenia.

AbstractCONTEXT:
Imaging and post-mortem studies provide converging evidence that patients with schizophrenia have a dysregulated developmental trajectory of frontal lobe myelination even in adulthood. Atypical antipsychotics have been shown to have a wide spectrum of efficacy across multiple psychiatric diseases and to be particularly efficacious in treatment resistant cases of disorders such as schizophrenia.
OBJECTIVE:
To test the a priori hypothesis that antipsychotic medications may differentially impact frontal lobe myelination in patients with schizophrenia.
DESIGN, SETTING, AND PARTICIPANTS:
Participants ranged in age from 18-35 years, were all male, and were recruited by a single group of investigators using the same criteria. Two cohorts of subjects with schizophrenia early in their disease who were treated either with oral risperidone (Ris) or fluphenazine decanoate (Fd) were imaged in conjunction with cohorts of healthy controls. Each cohort was imaged using a different MRI instrument using identical imaging sequences.
MAIN OUTCOME MEASURE:
MRI measures of frontal lobe white matter volume.
RESULTS:
We estimated differences due to differences in the MRI instruments used in the two studies in the two healthy control groups matched to the patient samples, adjusting for age and other covariates. We then statistically removed those differences (which we assumed were due to instrument effects) from the data in the schizophrenia samples by subtraction. Relative to the differences seen in controls, the two groups of schizophrenic patients differed in their pattern of frontal lobe structure with the Ris-treated group having significantly larger white matter volume than the Fd group.
CONCLUSIONS:
The results suggest that the choice of antipsychotic treatment may differentially impact brain myelination in adults with schizophrenia. Prospective studies are needed to confirm this finding. MRI can be used to dissect subtle differences in brain tissue characteristics and thus could help clarify the effect of pharmacologic treatments on neurodevelopmental and pathologic processes in vivo.
AuthorsGeorge Bartzokis, Po H Lu, Keith H Nuechterlein, Michael Gitlin, Clarissa Doi, Nancy Edwards, Christopher Lieu, Lori L Altshuler, Jim Mintz
JournalSchizophrenia research (Schizophr Res) Vol. 93 Issue 1-3 Pg. 13-22 (Jul 2007) ISSN: 0920-9964 [Print] Netherlands
PMID17407804 (Publication Type: Comparative Study, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)
Chemical References
  • Antipsychotic Agents
  • fluphenazine depot
  • Risperidone
  • Fluphenazine
Topics
  • Adolescent
  • Adult
  • Antipsychotic Agents (adverse effects, therapeutic use)
  • Cohort Studies
  • Fluphenazine (adverse effects, analogs & derivatives, therapeutic use)
  • Frontal Lobe (drug effects, pathology)
  • Humans
  • Image Processing, Computer-Assisted
  • Longitudinal Studies
  • Magnetic Resonance Imaging
  • Male
  • Nerve Fibers, Myelinated (drug effects)
  • Reference Values
  • Risperidone (adverse effects, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: